407 related articles for article (PubMed ID: 17079049)
1. Industrial perspective in ocular drug delivery.
Ali Y; Lehmussaari K
Adv Drug Deliv Rev; 2006 Nov; 58(11):1258-68. PubMed ID: 17079049
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
4. Strategies to improve oral drug bioavailability.
Gomez-Orellana I
Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
[TBL] [Abstract][Full Text] [Related]
5. Diverse approaches for the enhancement of oral drug bioavailability.
Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
[TBL] [Abstract][Full Text] [Related]
6. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery.
Jiao J
Adv Drug Deliv Rev; 2008 Dec; 60(15):1663-73. PubMed ID: 18845195
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches to ocular drug delivery.
Davis JL; Gilger BC; Robinson MR
Curr Opin Mol Ther; 2004 Apr; 6(2):195-205. PubMed ID: 15195932
[TBL] [Abstract][Full Text] [Related]
8. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
Short BG
Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
[TBL] [Abstract][Full Text] [Related]
9. Cyclodextrins in drug delivery.
Loftsson T; Jarho P; Másson M; Järvinen T
Expert Opin Drug Deliv; 2005 Mar; 2(2):335-51. PubMed ID: 16296758
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in ocular drug delivery.
Achouri D; Alhanout K; Piccerelle P; Andrieu V
Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
[TBL] [Abstract][Full Text] [Related]
11. Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
Müller CE
Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841
[TBL] [Abstract][Full Text] [Related]
12. Drug delivery systems - an overview.
Jain KK
Methods Mol Biol; 2008; 437():1-50. PubMed ID: 18369961
[TBL] [Abstract][Full Text] [Related]
13. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
14. [New research on the significance of polymers in pharmaceutical formulations].
Amighi K
Bull Mem Acad R Med Belg; 2001; 156(6 Pt 2):302-10. PubMed ID: 11928220
[TBL] [Abstract][Full Text] [Related]
15. Drug delivery systems for vitreoretinal diseases.
Yasukawa T; Ogura Y; Tabata Y; Kimura H; Wiedemann P; Honda Y
Prog Retin Eye Res; 2004 May; 23(3):253-81. PubMed ID: 15177203
[TBL] [Abstract][Full Text] [Related]
16. Sustained transscleral drug delivery.
Barocas VH; Balachandran RK
Expert Opin Drug Deliv; 2008 Jan; 5(1):1-10. PubMed ID: 18095925
[TBL] [Abstract][Full Text] [Related]
17. Drug delivery for optimised products: from product life-cycle management to first-generation product concepts.
Bhatt PP
Expert Opin Drug Deliv; 2005 Jan; 2(1):1-2. PubMed ID: 16296731
[No Abstract] [Full Text] [Related]
18. Nanosizing--oral formulation development and biopharmaceutical evaluation.
Kesisoglou F; Panmai S; Wu Y
Adv Drug Deliv Rev; 2007 Jul; 59(7):631-44. PubMed ID: 17601629
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology in ocular drug delivery.
Sahoo SK; Dilnawaz F; Krishnakumar S
Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
[TBL] [Abstract][Full Text] [Related]
20. Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview.
Almeida H; Amaral MH; Lobão P; Sousa Lobo JM
Expert Opin Drug Deliv; 2013 Sep; 10(9):1223-37. PubMed ID: 23688342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
